Ardelyx Company Profile (NASDAQ:ARDX)

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx, Inc. (NASDAQ:ARDX) announced its earnings results on Friday, May, 5th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.06. View Ardelyx's Earnings History.

Ardelyx is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Ardelyx.

5 brokerages have issued 12 month price objectives for Ardelyx's shares. Their predictions range from $12.00 to $24.00. On average, they expect Ardelyx's share price to reach $15.60 in the next year. View Analyst Ratings for Ardelyx.

Here are some recent quotes from research analysts about Ardelyx stock:

• 1. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)
• 2. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (5/23/2017)

Ardelyx saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,326,783 shares, an increase of 31.5% from the May 31st total of 1,008,745 shares. Based on an average trading volume of 579,916 shares, the days-to-cover ratio is presently 2.3 days. Currently, 4.4% of the company's shares are short sold.

Some companies that are related to Ardelyx include BioCryst Pharmaceuticals (BCRX), Geron Corporation (GERN), Bellicum Pharmaceuticals (BLCM), Reata Pharmaceuticals (RETA), Karyopharm Therapeutics (KPTI), MyoKardia (MYOK), Atara Biotherapeutics (ATRA), Ra Pharmctl (RARX), GlycoMimetics (GLYC), BioTime (BTX), Selecta Biosciences (SELB), BioSpecifics Technologies Corp (BSTC), Rigel Pharmaceuticals (RIGL), Merus N.V. (MRUS), Adaptimmune Therapeutics PLC (ADAP), Minerva Neurosciences (NERV), Corbus Pharmaceuticals Holdings (CRBP) and Edge Therapeutics (EDGE).

Ardelyx's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Michael G. Raab, President, Chief Executive Officer, Director
• Mark E. Kaufmann, Chief Financial Officer
• Reginal Seeto, Chief Operating Officer, Executive Vice President
• Jeremy S. Caldwell Ph.D., Executive Vice President, Chief Scientific Officer
• Paul Korner M.D., Executive Vice President, Chief Medical Officer
• Elizabeth Grammer Esq., Senior Vice President, General Counsel
• David P. Rosenbaum Ph.D., Chief Development Officer
• Robert H. Bazemore Jr., Independent Director
• William C. Bertrand Jr. Esq., Independent Director

Ardelyx's stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (0.00%), FMR LLC (0.00%), Perceptive Advisors LLC (3.98%), Vanguard Group Inc. (0.00%), First Manhattan Co. (2.23%) and RA Capital Management LLC (1.75%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell, Michael Raab and Nea 15 Gp, Llc. View Institutional Ownership Trends for Ardelyx.

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, First Manhattan Co., JPMorgan Chase & Co., Credit Suisse AG, Morgan Stanley, ProShare Advisors LLC and TD Asset Management Inc.. Company insiders that have sold Ardelyx stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs and Jeremy S Caldwell. View Insider Buying and Selling for Ardelyx.

Ardelyx's stock was acquired by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Teachers Advisors LLC, Sphera Funds Management LTD., Driehaus Capital Management LLC, Victory Capital Management Inc., Emory University and Perceptive Advisors LLC. Company insiders that have bought Ardelyx stock in the last two years include Gordon Ringold and Nea 15 Gp, Llc. View Insider Buying and Selling for Ardelyx.

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ardelyx stock can currently be purchased for approximately $5.25.